Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Operations (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Cash from Operations for 14 consecutive years, with 9184000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 22.04% year-over-year to 9184000.0, compared with a TTM value of 27591000.0 through Dec 2025, down 22.47%, and an annual FY2025 reading of 27591000.0, down 22.47% over the prior year.
  • Cash from Operations was 9184000.0 for Q4 2025 at Heron Therapeutics, down from 1331000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3371000.0 in Q3 2024 and bottomed at 62992000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 22958750.0, with a median of 18340000.0 recorded in 2023.
  • Peak annual rise in Cash from Operations hit 136.73% in 2024, while the deepest fall reached 579.84% in 2024.
  • Year by year, Cash from Operations stood at 45258000.0 in 2021, then rose by 17.07% to 37534000.0 in 2022, then surged by 106.54% to 2455000.0 in 2023, then plummeted by 579.84% to 11780000.0 in 2024, then rose by 22.04% to 9184000.0 in 2025.
  • Business Quant data shows Cash from Operations for HRTX at 9184000.0 in Q4 2025, 1331000.0 in Q3 2025, and 10868000.0 in Q2 2025.